Imprimis Pharmaceuticals Inc (IMMY)

[sloan14]

Phase III was successful.

In October 2009, Transdel Pharmaceuticals announced positive phase 3 study results for its lead topical pain drug, Ketotransdel®.

http://www.transdelpharma.com/products.html